Molecular analysis distinguishes metastatic disease from second cancers in patients with retinoblastoma

Hilary Racher, Sameh Soliman, Bob Argiropoulos, Helen S.L. Chan, Brenda L. Gallie, Renée Perrier, Donco Matevski, Diane Rushlow, Beata Piovesan, Furqan Shaikh, Heather MacDonald, Timothy W. Corson

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The pediatric ocular tumor retinoblastoma readily metastasizes, but these lesions can masquerade as histologically similar pediatric small round blue cell tumors. Since 98% of retinoblastomas have RB1 mutations and a characteristic genomic copy number “signature”, genetic analysis is an appealing adjunct to histopathology to distinguish retinoblastoma metastasis from second primary cancer in retinoblastoma patients. Here, we describe such an approach in two retinoblastoma cases. In patient one, allele-specific (AS)-PCR for a somatic nonsense mutation confirmed that a temple mass was metastatic retinoblastoma. In a second patient, a rib mass shared somatic copy number gains and losses with the primary tumor. For definitive diagnosis, however, an RB1 mutation was needed, but heterozygous promoter→exon 11 deletion was the only RB1 mutation detected in the primary tumor. We used a novel application of inverse PCR to identify the deletion breakpoint. Subsequently, AS-PCR designed for the breakpoint confirmed that the rib mass was metastatic retinoblastoma. These cases demonstrate that personalized molecular testing can confirm retinoblastoma metastases and rule out a second primary cancer, thereby helping to direct the clinical management.

Original languageEnglish (US)
Pages (from-to)359-363
Number of pages5
JournalCancer Genetics
Volume209
Issue number7-8
DOIs
StatePublished - Jul 1 2016

Keywords

  • Retinoblastoma
  • differential diagnosis
  • inverse PCR
  • metastasis
  • mutation detection
  • second primary tumor

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Molecular analysis distinguishes metastatic disease from second cancers in patients with retinoblastoma'. Together they form a unique fingerprint.

  • Cite this

    Racher, H., Soliman, S., Argiropoulos, B., Chan, H. S. L., Gallie, B. L., Perrier, R., Matevski, D., Rushlow, D., Piovesan, B., Shaikh, F., MacDonald, H., & Corson, T. W. (2016). Molecular analysis distinguishes metastatic disease from second cancers in patients with retinoblastoma. Cancer Genetics, 209(7-8), 359-363. https://doi.org/10.1016/j.cancergen.2016.06.001